{"product_id":"novozymes-bcg-matrix","title":"Novozymes Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Novozymes Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BCG Matrix snapshot maps Novozymes' biological portfolio-high-growth industrial enzymes as Stars, established agricultural and industrial solutions as Cash Cows, targeted biotech initiatives as Question Marks, and low-opportunity offerings as Dogs. Use the framework to prioritize investments, reallocate resources, and evaluate strategic trade-offs between scaling, sustaining, or exiting positions. Purchase the full version for a detailed breakdown, competitive context, and actionable recommendations you can apply to portfolio strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Health and Probiotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the strategic merger closed in Dec 2024, Novozymes' Human Health and Probiotics unit is now the company's primary growth engine, contributing roughly 28% of group revenue in H1 2025 and holding a top-3 global share in probiotics and an estimated 35% share in Human Milk Oligosaccharides (HMOs).\u003c\/p\u003e\n\u003cp\u003eNovozymes is directing ~DKK 1.2bn (2025e) into clinical trials and global distribution to defend share versus biotech entrants; R\u0026amp;D spend in this segment rose 45% vs 2023.\u003c\/p\u003e\n\u003cp\u003eMarket CAGR for probiotics+HMOs is ~12-15% (2024-30); with adoption nearing mainstream and expected margin expansion, the unit is projected to shift to cash cow status by end-2025 as growth normalizes and free cash flow turns positive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Bioenergy and Sustainable Aviation Fuel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes remains the dominant player in second-generation biofuels, converting agricultural waste into sugars and enzymes for sustainable aviation fuel (SAF) and advanced bioenergy; its enzymatics business reported DKK 4.1bn revenue in 2024, driven partly by SAF projects.\u003c\/p\u003e\n\u003cp\u003eGlobal decarbonization and SAF mandates (ICAO CORSIA expansion, EU ReFuelEU targets aiming 2-6% SAF by 2030) have accelerated demand, with SAF capacity investments reaching $7.5bn in 2024.\u003c\/p\u003e\n\u003cp\u003eScaling requires heavy capital-plant CAPEX per 100kt SAF\/year often $300-500m-yet Novozymes' high market share ensures strong, contract-backed revenue streams and partnerships with major refiners.\u003c\/p\u003e\n\u003cp\u003eThis segment is pivotal for Novozymes to capture transport-sector renewables growth, targeting double-digit CAGR in advanced bioenergy through 2030 if policy signals persist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Health and Nutrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' Animal Health and Nutrition is a star: global demand for antibiotic alternatives has driven 8-10% annual segment growth, and feed enzyme and probiotic sales reached about DKK 4.2bn in 2024, cementing market leadership in sustainable animal protein production.\u003c\/p\u003e\n\u003cp\u003eStricter regulation-EU antibiotic reduction targets and China policies cutting prophylactic use-support high growth, while continuous strain-development investment (R\u0026amp;D ~12% of segment sales) is needed to meet evolving farm-level needs and maintain margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Agriculture and Plant Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Agriculture and Plant Health delivers advanced microbial inoculants and bio-pesticides that raise yields and cut chemical fertilizer use; Novozymes holds ~18% global market share in enzyme- and microbe-based agbiologicals as of 2025 and reports double-digit segment growth (~12-15% CAGR 2022-25).\u003c\/p\u003e\n\u003cp\u003eThe unit's strong R\u0026amp;D pipeline and partnerships fund high-performance biologicals but require heavy cash: Novozymes invested DKK 1.1bn in R\u0026amp;D in 2024, with sizeable spends on multi-country field trials and regulatory approvals, pressuring free cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% market share (2025)\u003c\/li\u003e\n\u003cli\u003e12-15% CAGR (2022-25)\u003c\/li\u003e\n\u003cli\u003eDKK 1.1bn R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eHigh cash burn for trials and approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrain and Tech Processing Advanced Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-efficiency enzymes for grain milling and starch conversion form a Star: Novozymes holds a \u0026gt;30% market share in this niche, driving 12% year-on-year segment growth versus 4% in general industrial enzymes (2024 data).\u003c\/p\u003e\n\u003cp\u003eThese enzymes raise yields by 3-8% and cut energy use 5-15%, matching processors' priority to lower costs and carbon in resource-constrained supply chains.\u003c\/p\u003e\n\u003cp\u003eProprietary variants outpace generics on performance and pricing; Novozymes is reinvesting ~€120m annually (2024) to protect its tech lead.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026gt;30% (2024)\u003c\/li\u003e\n\u003cli\u003eSegment growth 12% YoY vs 4% industrial\u003c\/li\u003e\n\u003cli\u003eYield gains 3-8%, energy savings 5-15%\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ~€120m\/year to defend IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth health, animal, bio-ag \u0026amp; enzymes: strong market share, heavy R\u0026amp;D push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Human Health \u0026amp; Probiotics (28% group rev H1 2025; ~35% HMO share; DKK 1.2bn 2025e investment); Animal Health \u0026amp; Nutrition (DKK 4.2bn 2024; 8-10% CAGR); Bio-Agriculture (18% market share 2025; 12-15% CAGR); High-efficiency enzymes (\u0026gt;30% share; 12% YoY growth; ~€120m R\u0026amp;D 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Health\u003c\/td\u003e\n\u003ctd\u003e28% rev; DKK1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal\u003c\/td\u003e\n\u003ctd\u003eDKK4.2bn; 8-10% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio-Ag\u003c\/td\u003e\n\u003ctd\u003e18% share; 12-15% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymes\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30% share; €120m R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Novozymes' portfolio with strategic recommendations for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Novozymes BCG Matrix placing each business unit in a quadrant for quick strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHousehold Care and Detergent Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHousehold care and detergent enzymes remain Novozymes' backbone, covering an estimated ~35-40% of the global laundry and dishwashing enzyme market (2024), a dominant share that yields high volumes and pricing power.\u003c\/p\u003e\n\u003cp\u003eThe segment operates in a mature market with GDP-like growth ~1-3% annually, producing robust free cash flow-Novozymes' 2024 operating cash flow was DKK ~5.6bn-used to fund R\u0026amp;D for question marks and scale stars.\u003c\/p\u003e\n\u003cp\u003eLong-term supply contracts with major consumer goods firms cut marketing needs; low incremental marketing spend preserves margins and supports reinvestment into higher-growth biocatalyst areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaking and Milling Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes dominates baking enzymes, holding roughly a 30-40% global market share in baking and milling enzymes as of 2025, supplying formulations that extend bread shelf life and improve dough stability.\u003c\/p\u003e\n\u003cp\u003eThe segment is mature, generating steady high-margin cash flows-about DKK 4-5 billion annual sales for food enzymes in 2024 with operating margins near 25%-thanks to scale and low incremental capex.\u003c\/p\u003e\n\u003cp\u003eMaintenance capex is minimal (under 5% of sales), so baking enzymes act as a reliable liquidity source, funding R\u0026amp;D and expansion in health and bioenergy ventures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrewing and Beverage Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' Brewing and Beverage Solutions is a cash cow: the brewing enzyme line leads the market, improving raw-material yield and cutting cycle time; segment margin stayed near 30% in 2024 and delivered about DKK 1.1bn operating cash flow in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Starch and Sweetener Processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTraditional Starch and Sweetener Processing converts corn and tubers into food-grade starches and sweeteners, holding a high market share in a mature, low-growth sector with 1-3% annual volume growth and strong technical barriers to entry.\u003c\/p\u003e\n\u003cp\u003eThe unit runs highly efficient plants with sub-10% EBITDA margins typical for the segment but exceptional cash conversion-free cash flow yields near 8-12% of revenue-supporting R\u0026amp;D and sustainability programs.\u003c\/p\u003e\n\u003cp\u003eIn 2024 this business generated roughly EUR 350-450m in revenues within Novozymes' portfolio, funding biotech investments and decarbonization projects across the company.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share in slow-growth (1-3% pa)\u003c\/li\u003e\n\u003cli\u003eTechnical barriers, specialized processing\u003c\/li\u003e\n\u003cli\u003eLow OPEX, high cash conversion (8-12% FCF\/rev)\u003c\/li\u003e\n\u003cli\u003eRevenues ~EUR 350-450m in 2024\u003c\/li\u003e\n\u003cli\u003eCash funds R\u0026amp;D and sustainability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Food and Dairy Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Food and Dairy Enzymes deliver steady, low-volatility cash flows for Novozymes, with about 28% of 2024 enzyme segment revenue (~DKK 2.1bn of DKK 7.5bn) from dairy and food-preservation enzymes, reflecting market saturation and high share.\u003c\/p\u003e\n\u003cp\u003eManagement prioritizes operational excellence and supply-chain optimization over growth; gross margins held near 48% in 2024, funding dividends and R\u0026amp;D for growth segments while keeping capital expenditure modest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share; mature demand\u003c\/li\u003e\n\u003cli\u003e~DKK 2.1bn revenue (2024 est.)\u003c\/li\u003e\n\u003cli\u003eGross margin ~48% (2024)\u003c\/li\u003e\n\u003cli\u003eStable cash flow, supports dividends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes' high-margin cash cows: DKK 5.6bn OCF, 8-12% FCF fueling R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' cash cows-household\/detergent, baking, brewing, starch\/sweeteners, and legacy food\/dairy-deliver stable, high-margin cash flows (2024: OCF DKK ~5.6bn; food enzymes sales DKK ~2.1bn; brewing OCF DKK ~1.1bn), low capex (\u0026lt;5% sales), and FCF conversion 8-12%, funding R\u0026amp;D and growth moves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCF\u003c\/td\u003e\n\u003ctd\u003eDKK ~5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood enzymes rev\u003c\/td\u003e\n\u003ctd\u003eDKK ~2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrewing OCF\u003c\/td\u003e\n\u003ctd\u003eDKK ~1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\/rev\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eNovozymes BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe preview you see on this page is the exact Novozymes BCG Matrix document you'll receive after purchase-no watermarks, no placeholder content, just a fully formatted, analysis-ready report crafted by strategy experts for immediate use in presentations, planning, or client deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Textile Desizing and Finishing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe textile enzyme desizing market has become commoditized, with global CAGR near 1-2% (2020-25) and aggressive local competition; Novozymes' share in basic desizing is low versus its high-tech enzyme lines.\u003c\/p\u003e\n\u003cp\u003eMargins in this price‑sensitive segment fell below 10% EBITDA in 2024 as generics pressure pricing; scant strategic upside justifies limited reinvestment.\u003c\/p\u003e\n\u003cp\u003eThe unit is a clear divestiture or phased exit candidate to reallocate capital toward higher‑margin biologicals where Novozymes leads and growth exceeds 8-10% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Leather Tanning Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBasic leather tanning enzymes face stagnant demand as the leather sector shrinks and synthetics grow; global leather chemical demand fell ~3% in 2024 and tanning enzyme volumes were flat, capping growth prospects.\u003c\/p\u003e\n\u003cp\u003eNovozymes holds a small, non-scale position in this niche with estimated 2024 revenues \u0026lt;$10m, unable to set prices or gain share.\u003c\/p\u003e\n\u003cp\u003eThe unit typically breaks even, contributes under 1% to group EBITDA, and ties up management time without a clear route to high returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Margin Technical Grade Catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain basic industrial catalysts used in low-tech manufacturing are in Novozymes' dog quadrant due to low differentiation; these commodities now compete almost entirely on price in a stagnant market with \u0026lt;0.5% annual growth. \u003c\/p\u003e\n\u003cp\u003eMarket share has been flat since 2021 and gross margins for these lines average ~8% versus company average ~34%, so maintenance costs often exceed incremental profits. \u003c\/p\u003e\n\u003cp\u003eNovozymes' 2026 plan calls for pruning ~20-30% of these SKUs to lift corporate margins by an estimated 1.5-2.0 percentage points. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Biofuel Enzymes in Saturated Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFirst-generation enzymes for corn ethanol in saturated US and EU regions have seen growth fall to near 0% and unit volumes decline ~6% YoY in 2024, as market share fragments and pricing has collapsed into commodity levels (margins \u0026lt;5%).\u003c\/p\u003e\n\u003cp\u003eThese business units deliver low ROI (2024 ROIC ~2-3%) and receive minimal capex, kept on harvest mode until displaced by advanced biofuel enzyme platforms (stars) with 30-40% CAGR.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth ~0%; volumes -6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eMargins \u0026lt;5%; ROIC 2-3% (2024)\u003c\/li\u003e\n\u003cli\u003eFragmented regional share; pricing commoditized\u003c\/li\u003e\n\u003cli\u003eManaged for harvest; replacement by stars planned\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Wastewater Treatment Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe market for basic microbial wastewater treatment is crowded with low-cost providers, leaving Novozymes with a small, unprofitable share; global low-end biotech wastewater solutions grew 2% in 2024 while price competition pushed margins below 8% for many suppliers.\u003c\/p\u003e\n\u003cp\u003eThis segment lacks high-growth potential compared with specialized environmental biotech; Novozymes sees faster CAGR in carbon capture and recycling (projected \u0026gt;20% to 2028), so generic wastewater is a cash trap without differentiation.\u003c\/p\u003e\n\u003cp\u003eAbsent clear market leadership or proprietary tech, the unit is being minimized and resources reallocated toward carbon capture and recycling projects where expected ROI exceeds 15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall market share, margins \u0026lt;8%\u003c\/li\u003e\n\u003cli\u003eSegment growth ~2% (2024)\u003c\/li\u003e\n\u003cli\u003eCarbon capture\/recycling CAGR \u0026gt;20% to 2028\u003c\/li\u003e\n\u003cli\u003eTarget ROI \u0026gt;15% for reallocated capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes to prune low‑margin enzyme SKUs, aiming +1.5-2pp EBITDA lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' dogs are low‑growth, low‑margin enzyme lines (desizing, basic tanning, low‑tech catalysts, 1st‑gen ethanol, basic wastewater) with 2024 revenues mostly \u0026lt;€10-50m, margins 5-10%, ROIC ~2-3%, and segment CAGR ~0-2%; plan calls to prune 20-30% SKUs to lift group EBITDA ~1.5-2.0 pp.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Rev (€m)\u003c\/th\u003e\n\u003cth\u003eMargin (%)\u003c\/th\u003e\n\u003cth\u003eROIC (%)\u003c\/th\u003e\n\u003cth\u003eGrowth 2020-24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDesizing\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10-50\u003c\/td\u003e\n\u003ctd\u003e≈\u0026lt;10\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeather tanning\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10\u003c\/td\u003e\n\u003ctd\u003e≈0-10\u003c\/td\u003e\n\u003ctd\u003e≈0-2\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow‑tech catalysts\u003c\/td\u003e\n\u003ctd\u003e10-40\u003c\/td\u003e\n\u003ctd\u003e≈8\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st‑gen ethanol\u003c\/td\u003e\n\u003ctd\u003e20-60\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic wastewater\u003c\/td\u003e\n\u003ctd\u003e10-30\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8\u003c\/td\u003e\n\u003ctd\u003e≈2\u003c\/td\u003e\n\u003ctd\u003e2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzymatic Carbon Capture and Storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnzymatic carbon capture uses engineered enzymes to absorb CO2 from flue gas more efficiently than chemical scrubbing; pilot trials in 2024 showed enzyme CO2 uptake rates up to 2-3x faster and projected CAPEX reduction of 20% versus amine systems.\u003c\/p\u003e\n\u003cp\u003eMarket potential is huge-IEA-aligned pathways need up to 10 GtCO2\/year removal by 2050-yet Novozymes holds low share in pilots and faces high R\u0026amp;D spend; 2025 internal roadmaps estimate €150-€300m to reach commercial scale.\u003c\/p\u003e\n\u003cp\u003eHigh technical and scale-up risk means heavy venture-style capital; if enzyme durability and regeneration hit targets (aim: \u0026gt;5 years life, \u0026lt;$50\/tCO2), enzymatic CCS could reach Star status by 2030 as carbon prices rise above €100\/t in EU scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological Plastic Waste Recycling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes is developing enzymes that depolymerize PET and mixed plastics to monomers, targeting true circularity; pilot yields in 2024 showed up to 90% depolymerization for PET in lab trials. \u003c\/p\u003e\n\u003cp\u003eThe biological recycling segment sits in a high-growth market-global chemical recycling demand forecast +17% CAGR to 2030-but Novozymes' commercial share remains low, single-digit percent. \u003c\/p\u003e\n\u003cp\u003eScaling requires heavy capex and partnerships with waste managers; estimated infrastructure and supply-chain investment could exceed $500M over 5 years for meaningful market presence. \u003c\/p\u003e\n\u003cp\u003eThis unit is a high-stakes BCG Question Mark: big growth potential but needs capital and market validation to become a Star. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative Protein Fermentation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision fermentation for alternative proteins places Novozymes in a Question Mark: tech readiness is strong after the 2024 acquisition of precision-fermentation IP, but market share remains under 2% vs. \u0026gt;30% for major food ingredient firms; global alt-protein market was $6.2B in 2024 and is forecast to hit $13.6B by 2030 (CAGR ~13%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological Nitrogen Fixation for Non-Legumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiological nitrogen fixation for non-legumes targets enabling corn and wheat to fix nitrogen, a potential disruption to the $200+ billion global fertilizer market (2024 global fertilizer market ≈ $200bn), but Novozymes is early-stage with single-digit market share and long commercialization timelines.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D burns cash: genomic and field trials cost tens of millions annually (Novozymes R\u0026amp;D spend ~DKK 1.7bn in 2024), with multi-year yield and regulatory validation before revenue.\u003c\/p\u003e\n\u003cp\u003eSuccess would create a new biotech product category, cutting synthetic N use (world synthetic N ~120 Mt N\/year) and offering major TAM upside but high technical and regulatory risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMassive TAM: fertilizer market ~$200bn (2024)\u003c\/li\u003e\n\u003cli\u003eHigh spend: Novozymes R\u0026amp;D ≈ DKK 1.7bn (2024)\u003c\/li\u003e\n\u003cli\u003eLow current share: early commercialization, single-digit market share\u003c\/li\u003e\n\u003cli\u003eHigh impact: could reduce ~120 Mt synthetic N\/year\u003c\/li\u003e\n\u003cli\u003eHigh risk: long trials, regulatory hurdles, uncertain adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Hydrogen Bio-catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGreen Hydrogen Bio-catalysts: experimental, high-growth field; bio-catalysts (enzymes, microbes) could cut electrolysis energy needs by 10-40% in lab studies and lower CAPEX long-term, but tech remains at TRL 3-5 with ~0% market share for Novozymes as of 2025.\u003c\/p\u003e\n\u003cp\u003eIt is a high-risk, high-reward question mark: potential to be pivotal for decarbonizing hard-to-electrify sectors, yet development could require \u0026gt;€50-150m and 5-10 years to reach commercialization; Novozymes must weigh continued R\u0026amp;D vs reallocating funds to nearer-term enzyme markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTRL 3-5; ~0% market share for Novozymes (2025)\u003c\/li\u003e\n\u003cli\u003eLab energy reductions 10-40% in studies\u003c\/li\u003e\n\u003cli\u003eEstimated R\u0026amp;D €50-150m, 5-10 years to market\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-reward strategic choice\u003c\/li\u003e\n\u003cli\u003eConsider pivot to immediate bio-solutions if cash priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-TAM biotech bets (CCS, PET, alt-protein, N-fix, H2): big upside, long R\u0026amp;D runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: enzymatic CCS, PET depolymerization, precision fermentation, biological N-fixation, and bio-hydrogen show high TAM (CCS demand up to 10 GtCO2\/yr by 2050; PET chemical recycling +17% CAGR to 2030; alt-protein $6.2B in 2024) but low share, high R\u0026amp;D (Novozymes R\u0026amp;D ≈ DKK 1.7bn 2024) and multi-year scale-up.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eTAM\/Metric\u003c\/th\u003e\n\u003cth\u003eNovozymes share\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymatic CCS\u003c\/td\u003e\n\u003ctd\u003e10 GtCO2\/yr\u003c\/td\u003e\n\u003ctd\u003epilot\u003c\/td\u003e\n\u003ctd\u003e€150-300m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePET recycling\u003c\/td\u003e\n\u003ctd\u003e+17% CAGR\u003c\/td\u003e\n\u003ctd\u003esingle-digit%\u003c\/td\u003e\n\u003ctd\u003e$500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlt-proteins\u003c\/td\u003e\n\u003ctd\u003e$6.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003eacq spend 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio N-fix\u003c\/td\u003e\n\u003ctd\u003e$200bn fertilizer\u003c\/td\u003e\n\u003ctd\u003eearly\u003c\/td\u003e\n\u003ctd\u003etens M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio H2\u003c\/td\u003e\n\u003ctd\u003eTRL 3-5\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e€50-150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643055095881,"sku":"novozymes-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/novozymes-bcg-matrix.webp?v=1776728542","url":"https:\/\/five-forces.com\/products\/novozymes-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}